홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

라스미디탄

Lasmiditan

HCID 11610526
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
439239-90-4
표준 SMILES
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
InChIKey
XEDHVZKDSYZQBF-UHFFFAOYSA-N
분자식
C19H18F3N3O2
평균 분자량
377.4 g/mol
단동위원소 질량
377.13511131

개요

Lasmiditan is a DEA Schedule V controlled substance. Substances in the DEA Schedule V have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. It is a Depressants substance.

이름 및 식별자

우선 이름
Lasmiditan
IUPAC
2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridinyl]benzamide
현지명
라스미디탄
영어명
LasMiditan
분자식
C19H18F3N3O2
분자량
377.36

이름 및 동의어

Lasmiditan439239-90-4COL-1442,4,6-Trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl)benzamide2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamideCOL 144760I9WM792DTXSID40469435lasmiditanumRefChem:58578DTXCID002034182,4,6-trifluoro-n-(6-((1-methylpiperidin-4-yl)carbonyl)pyridin-2yl)benzamide
이름 더 보기
라스미디탄LasMiditan (COL-1442,4-difluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl)benzamideCS-2381LamiditamLamiditanLasmiditant13C-Lasmiditan
MFCD18633238ReyvowLY573144lasmitidan2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridinyl]benzamide2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide2,4,6-tris(fluoranyl)-N-[6-(1-methylpiperidin-4-yl)carbonylpyridin-2-yl]benzamide

데이터베이스 식별자

물성

구조 계산 물성보충 중

XLogP
2.8
극성 표면적
62.3 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
7
회전 가능 결합 수
4
무거운 원자 수
27
형식 전하
0
복잡도
530

실험 및 물리화학적 성질

Drugs · 3건

DEA Schedule V Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Unknown

Human Drugs · 3건

Breast Feeding; Lactation; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Vasoconstrictor Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

물리화학적 성질

녹는점
255 ℃ · 255℃
끓는 점
433.3 · 433.3±45.0 °C(Predicted)
밀도
1.351 · 1.351
저장 조건
-20 °C · -20°C Freezer, Under inert atmosphere
용해도
클로로포름 (약간 용해됨), DMSO (약간 용해됨)
산도 계수 (pKa)
9.91 · 9.91±0.70(Predicted)
물리적 상태
고체
색상
흰색에서 황백색까지

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

유해성 정보

Regulatory InformationDEA schedule V controlled substance

독성 정보

Hepatotoxicity · 1건

In preregistration controlled trials of lasmiditan in several thousand patients, mild-to-moderate serum aminotransferase elevations arose in a small percentage of patients (1% or less) and overall rates were not different from those in placebo recipients. In the controlled trials and subsequently with general use, there have been no reports of liver injury with symptoms or jaundice attributed to lasmiditan.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

신호 어
Warning
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H319

화학 및 산업

약리 정보

ATC Code · 2건

N - Nervous system

QN - Nervous system

Protein BindingLasmiditan exhibits a concentration-independent plasma protein binding of approximately 55-60%.
Pharmacodynamics · 1건

Lasmiditan belongs to a new and novel class of acute anti-migraine medications that exert their effects via inhibition of neuronal firing rather than vasoconstriction of cerebral arteries. Lasmiditan appears to have a relatively quick onset of action (an important characteristic in acute migraine treatment) with some patients reporting benefit within 20 minutes. Due to its ability to cause CNS depression (e.g. drowsiness, dizziness), lasmiditan may cause significant driving impairment and patients should be advised not to participate in activities requiring mental alertness for at least 8 hours after dosing. Lasmiditan may carry some potential for abuse and should be used with caution in patients who may be at risk of drug abuse - its controlled substance scheduling is currently under review in the United States by the Drug Enforcement Administration (DEA). The safety of lasmiditan in pregnancy is unknown and is currently being monitored with a pregnancy exposure registry created by Eli Lilly and Company.

Mechanism of Action · 1건

The acute treatment of migraine headaches has, in the past, been achieved via constriction of cerebral blood vessels, as the acute dilation of these vessels observed during migraines was thought to be the cause of the associated pain. The neurogenic hypothesis of migraine pathophysiology, an alternative to the vascular hypothesis, suggests that cerebral vasodilation is a secondary mechanism in migraine pathogenesis, and that the main contributor to migraine headache pain is the increased pathogenic firing of trigeminal nerve pathways. While the precise mechanism of action of lasmiditan is unclear, it likely supports this neurogenic hypothesis by exerting its therapeutic effects through potent and selective agonism of the 5-HT<sub>1F</sub> receptor. 5-HT<sub>1F</sub> receptors are found in both the central and peripheral nervous system (on the central and peripheral ends of trigeminal neurons) and appear to contribute to hyperpolarization of nerve terminals and inhibition of trigeminal neuronal activity. Lasmiditan's agonism at these receptors may, therefore, inhibit the firing of trigeminal nerves responsible for migraine headache pain. Lasmiditan has virtually no affinity for other 5-HT receptor subtypes or monoamine receptors (e.g. adrenergic, dopaminergic).

관련 반응

14건
반응 기록 만들기
HRID 30219 반응식
HRID 30219반응물로
HRID 30225 반응식
HRID 30225반응물로
HRID 404239 반응식
HRID 404239반응물로
HRID 404245 반응식
HRID 404245반응물로
HRID 666419 반응식
HRID 666419생성물로
HRID 685587 반응식
HRID 685587반응물로
HRID 1667344 반응식
HRID 1667344반응물로
HRID 1667350 반응식
HRID 1667350반응물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
CAS
439239-90-4
PubChem CID
11610526
DTXSID
DTXSID40469435
ChEMBL
CHEMBL3039520
UNII
760I9WM792
Nikkaji
J2.994.454G
Biological Half-LifeThe mean elimination half-life of lasmiditan is 5.7 hours.
Metabolism/Metabolites · 1건

The hepatic and extra-hepatic metabolism of lasmiditan is catalyzed primarily by non-CYP enzymes, with ketone reduction appearing to be the primary pathway. While the specific enzymes involved in the metabolism of lasmiditan have not been elucidated, FDA labeling states that the following enzymes are _not_ involved in its metabolism: monoamine oxidases, CYP450 reductase, xanthine oxidase, alcohol dehydrogenase, aldehyde dehydrogenase, and aldo-keto reductases. The metabolites of lasmiditan have not been characterized in published research, but two of its metabolites (M7 and M18) are considered to be pharmacologically inactive.

MeSH Pharmacological ClassificationEndogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS.
Absorption, Distribution and Excretion · 3건

Oral absorption of lasmiditan is quick, with a median tmax of 1.8 hours. An open-label study looking at absorption pharmacokinetics found the Cmax and AUC0-t of lasmiditan following oral administration to be 322.8 ± 122.0 ng/mL and 1892 ± 746.0 ng.h/mL, respectively. The oral bioavailability of lasmiditan has been reported as approximately 40%. Co-administration of lasmiditan with a high-fat meal increased its Cmax and AUC by 22% and 19%, respectively, and delayed Tmax by approximately 1 hour - these differences in absorption are relatively minor and unlikely to be clinically significant. Similarly, severe renal impairment and mild-moderate hepatic impairment were found to increase both AUC and Cmax, but not to a clinically significant extent.

Lasmiditan is eliminated primarily via metabolism, with renal excretion accounting for a small fraction of its total elimination. Of the small amount of drug found in the urine post-dose, approximately 66% is comprised of lasmiditan's S-M8 metabolite. Only 3% of an administered dose of lasmiditan was recovered unchanged in the urine, further implying a relatively extensive metabolism of this drug.

Lasmiditan has been shown to penetrate the blood-brain barrier.

응용 분야 · 2건

개요Lasmiditan (Item No. 28369) is an analytical reference standard categorized as an agonist of the serotonin (5-HT) receptor subtype 5-HT1F. Formulations containing lasmiditan have been used in the treatment of migraine headache. Lasmiditan has low abuse potential. Lasmiditan is regulated as a Schedule V compound in the United States. This product is intended for research and forensic applications.

용도Lasmiditan is used in diagnosing, treating and/or preventing periodontal disease and/or tooth loss.

상·하류 제품 정보

상류 원료

N-Methoxy-N,1-diMethylpiperidine-4-carboxaMide(6-a미노피리딘-2-일)(1-메틸피페리딘-4-일)메타논2-Amino-6-bromopyridine2,4,6-TRIFLUOROBENZOYL염화물4-피페리딘카르보닐클로라이드,1-메틸-(9CI)1-메틸-피페리딘-4-카르복실산4-클로로-N-메틸피페리딘